
Case report: major Alzheimer's symptom improvement after fecal microbiota transplantation
Louis shares a case report of an 82-year-old man with Alzheimer's whose cognition improved rapidly after FMT. A single case cannot show effectiveness.
64 posts (29 primarily about this topic) · 9 reposts and set-aside posts not shown

Louis shares a case report of an 82-year-old man with Alzheimer's whose cognition improved rapidly after FMT. A single case cannot show effectiveness.
Louis summarizes the oatmeal study, noting participants had BMI over 30 with metabolic syndrome and ate 1100-1200 kcal/day; controls on the same diet did not see the same benefit.

Louis highlights a small human trial in which berberine reduced atherosclerotic plaque score, with a proposed mechanism of lowering gut-derived TMAO by acting on TMAO-producing gut bacteria. The sample is small and the comparison group was not randomized to the same degree as a large trial, so this is hypothesis-generating.

Louis explains the University of Bonn RCT: 300 g/day oatmeal for 2 days with calorie restriction cut LDL about 10%, linked to gut microbiome phenolic metabolites, and persisted 6 weeks. He recommends slow-cook steel-cut oats.

Louis highlights a randomized trial in which one-for-one replacement of refined starch with resistant starch cut liver fat in half in 4 months. The proposed mechanism is microbiome changes and more short-chain fatty acids.

A written review of how TMAO forms from choline and carnitine via gut bacteria and the liver, and how to lower it. It points to less red meat and egg yolk, a fiber-rich Mediterranean-style diet, polyphenols and allicin, and statins and metformin. Gokhan says TMAO is not his top concern but worth knowing; he mentions a small human berberine trial that lowered TMAO and plaque.

Long summary arguing fiber is a bioactive longevity tool. The WHO-commissioned Reynolds 2019 meta-analysis found 15-30% lower all-cause mortality at 25-29 g/day, with benefits continuing per extra 8 g; newer NHANES data suggest diminishing returns past ~30 g/day. It describes mechanisms including butyrate-driven epigenetic effects and gut barrier reinforcement against toxins such as microplastics.

Louis recommends a Laurie Marbas article arguing that fibers differ in what they do in the body. The shared excerpt describes a 1978 experiment where the same fiber blunted a glucose spike only while it formed a thick gel, and proposes thinking of gel, feed and sweep fibers rather than soluble versus insoluble.
Louis recommends eating whole grains as intact as possible (steel-cut oats, wheat berries rather than finely ground flour) and refrigerating cooked grains for 24 hours to convert starch into resistant starch. Resistant starch is digested slowly and feeds gut bacteria.
A first-of-its-kind Memorial Sloan Kettering trial gave 20 overweight people with precursor blood disorders 12 weeks of plant-based meals with coaching. None had progressed at one year, and two with previously progressing disease improved. Researchers think increased gut butyrate may be involved; a 150-person trial (NUTRIVENTION-3) is enrolling.
A Cleveland Clinic randomized trial (not egg-industry funded, with TMAO discoverer Stanley Hazen) found choline bitartrate supplements raised TMAO and platelet reactivity, but four large eggs a day or phosphatidylcholine supplements did not.
Louis rebuts carnivore influencers' claims about the Hadza hunter-gatherers. Their diets are well studied: about 70% of calories from plants (tubers, berries, baobab) plus honey and lean game meat, making them low fat, moderate protein and high in natural sugar and starch. Their LDL is very low (62 mg/dL), heart disease risk is low, and their gut microbiome reflects a high-fiber plant diet.
Louis rebuts claims that eggs raise AFib risk via TMAO by pointing to an earlier randomized trial from the same Cleveland Clinic group. In that trial, eating eggs or taking phosphatidylcholine did not raise TMAO, whereas choline bitartrate supplements did. The trial was not funded by the egg industry.
A news item on an international Monash University study connecting constipation with higher risk of MACE (heart attack, stroke, heart failure). Constipation affects about 14% of people, so the authors argue gut health deserves attention in cardiovascular prevention.

Louis argues berberine's very low oral bioavailability (<1%) means its main anti-diabetic action is via gut bacteria, unlike metformin. The shared post cites human pharmacokinetics (Spinozzi 2014) finding mostly the metabolite berberrubine in plasma.
Louis quotes Harvard's Nutrition Source on yogurt. Cohorts of 120,877 people suggested protection from weight gain, and two meta-analyses of prospective cohorts found 18% and 14% lower type 2 diabetes risk with daily yogurt. Helpful bacteria are suggested to reduce inflammation or improve insulin action, though the mechanism is unclear.

Louis shares an ATVB editorial describing statin-induced gut microbiota changes as a candidate mechanism for statin-associated new-onset type 2 diabetes. The editorial says causality still needs larger sequencing studies. Louis adds that in JUPITER, high-dose rosuvastatin raised A1C by 0.1, bringing diabetes diagnosis about 5.4 weeks earlier over 2 years, a small but real effect.

Louis shares a Popular Science item noting fecal transplants have shown promise against some cancers, and speculates that trials in CVD and diabetes will follow, mentioning published reports of some people 'cured' of obesity. No data are given in the post.

Louis notes high fructose causes fatty liver in animals, yet whole fruit is linked to lower fatty liver risk in humans. He cites a 2025 mouse study where inulin fiber changed gut bacteria so fructose was broken down in the intestine before reaching the liver, which could partly explain it; no human trial has tested that mechanism.
The poster shares a Kevin Klatt video concluding that the science on TMAO causality is complicated and uncertain. He summarizes that gut bacteria turn choline, carnitine and betaine into TMA, the liver converts TMA to TMAO in an insulin-dependent step, kidneys clear it, and fish raise it transiently despite lower heart risk.
Louis shares a video on oats lowering cholesterol with a microbiome mechanism. The video is unavailable so no details survive.
A detailed explainer on ImP, a gut-microbial metabolite elevated in type 2 diabetes, atherosclerosis, heart failure, kidney disease and fatty liver. It is made from dietary histidine by specific bacteria in dysbiotic guts and is more tied to microbiome composition than to histidine intake, so a diverse, high-fiber microbiome is protective.
Louis asks whether group members take Akkermansia probiotics, often advertised as a natural GLP-1 booster, and points to a Harvard Medical School report linking Akkermansia levels in the gut to poor bone health. No numbers are given in the post.
A Nature paper reports that imidazole propionate (ImP) is independently associated with cardiovascular disease and causes atherosclerosis in mice through inflammation via the I1 imidazoline receptor. Blocking that receptor could become a cholesterol-independent therapy.
A University of Connecticut meta-analysis of nine studies linked regular kimchi intake to better cardiometabolic markers. The blood pressure benefit is attributed to potassium and fermentation bacteria despite kimchi's high sodium, though most studies were done in Korea.
Louis quotes a 2018 review concluding that gut microbiota participate in metformin's glucose-lowering effects in diabetes. Metformin alters gut bacterial composition, but the exact mechanisms still need to be worked out.

A short post defining prebiotics as non-digestible fibers feeding beneficial gut bacteria and probiotics as live bacteria that make up the beneficial portion of the gut microbiome.

Louis shares Layne Norton's summary of a new long-term randomized trial of artificial sweeteners during weight-loss maintenance, which found better weight maintenance and no adverse cardiometabolic effects versus a low-sugar diet alone, with gut findings worth more study. Louis does not recommend sweeteners but wants the evidence stated accurately.
Louis shares a 2016 randomized double-blind trial in which 12 weeks of daily Lactobacillus and Bifidobacterium probiotics yielded a moderate but significant improvement in Alzheimer's patients' cognitive scores. It was a small trial.
Louis highlights an npj Biofilms and Microbiomes paper showing raw garlic juice and allicin reduce TMAO production via gut microbiota. In people with high TMAO production, a week of raw garlic juice reduced TMAO formation, increased microbial diversity and beneficial bacteria; in mice allicin ameliorated atherosclerosis. He notes cooking destroys allicin.
Louis shares a news report on a Cell Reports Medicine study finding that once or twice daily is the 'Goldilocks zone' for stool frequency. Constipation raised blood levels of toxins such as p-cresol sulfate and indoxyl sulfate that burden the kidneys, while diarrhea was linked to excess bile acid loss. More fruit and vegetables, water, exercise and a plant-dominant diet characterized the Goldilocks group.
Louis shares a 2023 Frontiers in Nutrition randomized controlled pilot study testing kombucha tea as an anti-hyperglycemic agent in people with diabetes. The report says kombucha significantly lowered fasting blood glucose, but it is a small pilot.

Louis shares Luigi Fontana's summary of a large prospective cohort study in women showing that eating nuts, seeds, corn or seeded fruit did not increase diverticulitis risk, while healthy diet patterns (DASH, Mediterranean-style) were linked to lower risk. He notes his mother with diverticulosis was told to avoid nuts for years. Peripheral to heart health but relevant to nut-eating advice.

Image post listing strategies for microbiome health, tagged with fermented foods. Details not given in text.
Admin explains that beyond LDL, BP, BMI and triglycerides, chronic inflammation driven by viral infections, oral bacteria, gut metabolites (TMAO, imidazole propionate) and microplastics contributes to atherosclerosis. He lists personal habits (fiber, flossing, dental cleanings, flu vaccine, air purifier, organic food) and links his earlier posts.
Louis describes eating only two meals per day for eight years and argues that cutting calories and avoiding snacking is among the most useful things for health. He shares a Tim Spector video suggesting this pattern may also benefit the gut microbiome.

Medscape reports that coffee's effect on gut motility seems to involve other compounds interacting with microbiota, as caffeine alone did not speed recovery after GI surgery.

A shared summary of a Cell Metabolism study in which gut-microbe-produced D-lactate drives hepatic glucose and fat overproduction in obese mice and humans. Researchers also developed a gut 'substrate trap' to counter it. Posted with hashtags only; details come from the shared text.
Louis explains the appendix is not vestigial: it is part of the lymphatic system and shelters beneficial bacteria to repopulate the colon after illness or diarrhea.

Louis shares a summary of a double-blind precision RCT in 240 adults with prior colorectal polyps taking magnesium glycinate for 12 weeks, dosed to lower the calcium:magnesium ratio. In participants with a normal TRPM7 'magnesium gate', beneficial bacteria rose, with effects strongest in women.

A shared explainer says fiber varies independently in solubility, viscosity, fermentability and structure. Cellulose is insoluble, non-viscous, barely fermented; beta-glucan is soluble and highly viscous.
Canadian researchers found D-lactate made by gut bacteria signals the liver to produce excess glucose and fat in obese mice and humans. An oral polymer trap binding it in the gut improved glucose control, insulin resistance and liver inflammation in mice without changing diet or weight.
Louis highlights a phase 2 RCT in patients with metabolic syndrome where L-carnitine did not change total carotid plaque volume but increased plaque stenosis within 6 months versus placebo. The proposed mechanism is TMAO production, since carnitine is abundant in red meat, but Louis notes TMAO could be a marker for another causal factor. He calls it extremely concerning.
A Frontiers in Nutrition review suggests the Mediterranean diet counters obesity-driven inflammation by modulating gut microbiota and metabolites such as short-chain fatty acids and bile acids.
Explains that eating increases gut permeability, letting bacterial lipopolysaccharide (LPS) enter the blood and trigger inflammation, especially after meals high in saturated fat and sugar and low in fiber. Human studies suggest omega-3s reduce this response, though the clinical significance of the spikes is unclear.

A shared post says studies show metformin increases helpful gut species such as Akkermansia and Bacteroides that improve glucose control. Findings are mostly in animals and organoids; no bacteria have replaced metformin in large human trials.
Louis quotes a pharmacist's simple test: psyllium forms a thick gel in water while inulin dissolves clear. Only the gel-forming fibers trap bile acids, making the liver pull cholesterol from the blood, so for LDL choose psyllium or oat/barley beta-glucan, while inulin is a fine prebiotic.

A Nature Medicine study of 77 healthy Tanzanian men tested a switch between a traditional Kilimanjaro diet and a Western diet, plus a Western diet with the fermented banana drink mbege. The Western diet quickly increased weight and inflammatory and cardiometabolic proteins, while the heritage diet and mbege reduced inflammatory markers.
A phase II trial in Science Advances found that the constipation drug lubiprostone (16 ug daily) preserved eGFR over 24 weeks versus decline on placebo. Surprisingly, it did not cut uremic toxins; instead it shifted the gut microbiome and raised spermidine. Kidney disease commonly accompanies heart disease.

Louis shares a summary of a Life Metabolism study in 160 coronary artery disease participants plus human blood and mice. Intermittent fasting appeared to inhibit platelet activation and clot formation through increased gut microbial production of indole-3-propionic acid.

A shared summary of research on urolithin A, a compound gut bacteria make from ellagitannins in pomegranate, walnuts and berries. The poster notes most of the evidence is preclinical in animals and says it may have value in heart failure. The summary also mentions human trials published in Nature Medicine.
A study found the gut-bacteria peptide corisin is elevated in diabetic patients with CKD and tracks with severity. In mice, corisin travels to the kidney on albumin and accelerates aging, scarring and cell death, and a neutralizing antibody reduced kidney damage. Gokhan notes CKD almost always accompanies heart disease.

A shared infographic describes bidirectional gut-brain communication: vagus and enteric neural signaling, microbiota effects on the HPA axis and hormones such as GLP-1, immune cytokines, and metabolites like short-chain fatty acids. Louis adds that gut health is brain health.

Louis shares a Medscape item saying that certain probiotics can lower cholesterol, reduce inflammation and support heart and circulatory health. No details are given in the post.
Louis quotes Scientific American: the body makes its own incretin hormones such as GLP-1 and PYY, and gut bacteria ferment indigestible fiber and polyphenols into molecules that stimulate them. These hormones help regulate blood sugar, appetite and the speed of food moving through the gut (the 'colonic brake'). This suggests whole plant foods support the same pathways targeted by Ozempic and Wegovy.

Louis reshares a figure showing how high-fat, low-fiber diets and additives like emulsifiers and sweeteners shift microbial balance, weaken the gut barrier and drive low-grade inflammation linked to chronic disease. Fiber and short-chain fatty acids are highlighted.

The shared description of the DIABMET-FMT randomized trial says repeated fecal microbiota transplant capsules from lean, metabolically healthy donors improved insulin sensitivity, microbiome diversity and short-chain fatty acid production in adults with type 2 diabetes, without diet, drug or exercise changes. The poster sees it as evidence that the microbiome contributes to diabetes in some people. The details come from the post only and could not be verified here.

Cleveland Clinic researchers analyzed blood samples from over 5,000 people undergoing heart procedures and found TMAO, made by gut bacteria from nutrients in red meat and other animal products, was linked to higher AFib risk. Cell experiments suggested TMAO may alter the heart's electrical environment. Louis frames it as TMAO possibly raising AFib risk.

Louis reshares a figure showing how an unhealthy microbiome weakens the gut barrier, lets bacterial toxins leak into the bloodstream and drives chronic inflammation and metabolic dysfunction.

Louis shares data that fatty liver prevalence exceeds 50% in over-50s in a study of about 4,000 people, and stresses choline helps export liver fat. Phosphatidylcholine did not raise TMAO in a Cleveland Clinic RCT.

A shared summary of a study comparing 31 habitual coffee drinkers (3-5 cups/day) with 31 non-drinkers, assessing microbiome, mood and stress, including a two-week abstinence period.

Louis shares a Stanford Medicine 'Five facts' article on fiber, which feeds the gut microbiome and supports digestion yet most people don't get enough. The post itself contains no further detail.
A video from a medical-education channel on how urolithin A, made by gut bacteria from pomegranate and walnut ellagitannins, may help the stiff heart of HFpEF through mitochondrial quality control. The post describes the work as pre-clinical.
Louis shares a Tim Spector clip arguing elimination diets can damage the microbiome, damage that may be hard to repair, so short-term benefits should be weighed against long-term risk.